Article

NicOx, Pfizer announce phase II trial of latanoprost derivative

NicOx and Pfizer will initiate a phase II, dose-finding study of its PF-03187207 compound for the treatment of patients with glaucoma and ocular hypertension. The 28-day trial is designed to compare the safety and efficacy of the drug with that of latanoprost (Xalatan, Pfizer Ophthalmics).

Key Points

Sophia Antipolis, France-NicOx and Pfizer will initiate a phase II, dose-finding study of its PF-03187207 compound for the treatment of patients with glaucoma and ocular hypertension.

The 28-day trial is designed to compare the safety and efficacy of the drug with that of latanoprost (Xalatan, Pfizer Ophthal mics). The trial will involve parallel groups in a randomized, double-masked study and will enroll about 150 patients with primary open-angle glaucoma in one or both eyes.

This first clinical trial will evaluate the change in diurnal IOP at day 28. Secondary endpoints will include the change in IOP from baseline at the study center visits at four points during the trial, the proportion of patients at target IOP across all study visits, and safety.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.